TRN2: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: TRN-GTT4-1

NCBI ID: G791226

TRN-GTT4-1

Other Name(s): TRN2 | TRNAN2 | Transfer RNA-Asn (GTT) 4-1 | tRNA-Asn (anticodon GTT) 4-1

TRN2: A Potential Drug Target and Biomarker for Neurological Disorders

TRN-GTT4-1 (TRN2), a protein expressed in the brain, has been identified as a potential drug target (TRN2) and a biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases.

TRN2 is a transmembrane protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling.

TRN2 has been shown to be involved in a variety of physiological processes, including neuronal communication, neurotransmitter release, and inflammation. It has been shown to interact with several other proteins, including the neurotransmitter dopamine, the GPCR尾2R, and the transduction protein TrkB.

TRN2 has also been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease and Parkinson's disease. Studies have shown that TRN2 is overexpressed or downregulated in the brains of individuals with these disorders, and that these changes can contribute to the development of neurodegeneration.

In addition to its potential role as a drug target, TRN2 has also been identified as a potential biomarker for these disorders. Studies have shown that TRN2 levels are significantly decreased in the brains of individuals with Alzheimer's disease and Parkinson's disease, and that these changes can be detected using TRN2 antibodies or TRN2-specific probes.

TRN2 has also been shown to be involved in the regulation of pain perception and neuroinflammation. Studies have shown that TRN2 is involved in the neurotransmitter release of pain modulators, such as opioids, and that it is also involved in the regulation of neuroinflammation.

In conclusion, TRN2 is a protein that has been shown to be involved in a variety of physiological processes, including neuronal communication, neurotransmitter release, and inflammation. It has also been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease and Parkinson's disease. In addition to its potential role as a drug target, TRN2 has also been identified as a potential biomarker for these disorders. Further research is needed to fully understand the role of TRN2 in these processes and to develop effective treatments for these disorders.

Protein Name: TRNA-Asn (anticodon GTT) 4-1

The "TRN-GTT4-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRN-GTT4-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets